Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly
progressing blood cancer with a poor overall prognosis. AML is
relatively rare, and predominantly affects older adults. AML is a
heterogeneous disease, and many subtypes have been identified. The
current standard of care consists of cytarabine-based chemotherapy,
which can often achieve remission. However, th majority of patients
relapse, and survival rates are grim. There are clear unmet needs for
treatments that can prolong the overall survival of these patients, but
drug manufacturers have struggled to gain regulatory approval for new
therapies.

Key Questions Answered

Which AML patients have the greatest unmet needs?

What are the R&D strategies drug makers are pursuing in the AML space?

Why has it been so difficult for Pharma to develop successful
therapies for AML?

How are players aiming to circumvent difficulties that have
historically plagued AML drug development?

What are the most promising pipeline agents for AML? How do their
clinical and commercial attributes compare to one another?

What opportunities will remain following the launch of these pipeline
agents?

Do KOLs see a role for targeted therapies and immunotherapies in the
treatment of AML?